OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
February 01, 2012
A technical forum featuring Catalent Pharma Solutions, SAFC, and Neuland Laboratories.
The author describes an equation that can be used to define the Quality relationship between a contract manufacturing organization and a client, including how to factor in both party's needs and regulatory commitments.
The author examines recent examples of preferred-provider collaborations.
Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Each developing economy has unique economic, political, and cultural issues that help define its pharmaceutical market. To succeed, multinational pharmaceutical companies will have to adapt differently.
The author examines the opportunities and positioning of contract service providers.
January 02, 2012
Pressure to approve new user fees opens the door to action on drug shortages, prices, and regulation.
As part of the BRIC bloc with Russia, India, and China, Brazil is one of the world's leading emerging economies and is also considered by IMS Health to be one of seven pharmerging nations, which also include Mexico, Turkey, and South Korea.
The European Union market takes steps toward continuous processing and modular facilities.